Register Now - $40

DURATION:
1 hour
CREDIT:
1 AMA PRA Category 1 Creditâ„¢, 1 Nursing Contact Hour (1 Pharmacologic Hour)

INSTRUCTORS:

Neal Rouzier, MD
Faculty Chairman

During this course, Dr. Rouzier reviews the current endocrine society guidelines on the use of testosterone in women (which is separate from JAMA guidelines).  As would be expected, their recommendation is to treat only if the woman has a definitive diagnosis of HSDD.  The discussion centers on the lack of reliable blood tests or levels to diagnose or monitor testosterone deficiency.  They state that symptoms do not correlate with numbers, yet they go on to say that levels should be monitored, and they restrict treatment based on a number.

Studies show there are protective effects on the endothelium as well as neuroprotective with testosterone replacement.  Rebecca Glasser reports that adequate amounts of testosterone are essential for optimal health, immune function and disease prevention.

Objectives:

Upon completion of this workshop, the healthcare professional will be able to:

  1. Review and contrast the vast array of differing opinions, regarding the diagnosis and treatment of testosterone deficiency in women.
  2. Recognize that I am extremely biased, but only based on a review of >60 years of report/publications/RCT’s/observational prospective long-term studies that should not be ignored.
  3. Recall that everyone that writes a paper/article/story has a strong confirmation bias as to their paper’s agenda.
  4. Review the 20-year clinical experiences as well as multiple papers published in the most peer-reviewed OB/GYN journals by the most respected breast cancer researcher and hormone expert, Rebecca Glasser.
  5. Identify the two most important papers that must be given to each and every woman that is treated with testosterone.
  6. Contrast real world experience demonstrating that supraphysiologic levels are necessary for symptomatic improvement. Symptoms dictate treatment and adjustment, not levels.
  7. Review the data demonstrating that serum levels do not correlate with symptoms. Serum levels should not be utilized/tested as they are not predictive of improvement and are inconsistent.  Therapy should be  adjusted based on symptom improvement and side effects and not on serum levels.